Grating visual acuity results in the early treatment for retinopathy of prematurity study

Velma Dobson, Graham E. Quinn, C. Gail Summers, Robert J. Hardy, Betty Tung, William V. Good

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Objective: To compare grating (resolution) visual acuity at 6 years of age in eyes that received early treatment (ET) for high-risk prethreshold retinopathy of prematurity (ROP) with that in eyes that underwent conventional management (CM). Methods: In a randomized clinical trial, infants with bilateral, high-risk prethreshold ROP (n=317) had one eye undergo ET and the other eye undergo CM, with treatment only if ROP progressed to threshold severity. For asymmetric cases (n=84), the high-risk prethreshold eye was randomized to ET or CM. Main Outcome Measure: Grating visual acuity measured at 6 years of age by masked testers using Teller acuity cards. Results: Monocular grating acuity results were obtained from 317 of 370 surviving children (85.6%). Analysis of grating acuity results for all study participants with high-risk prethreshold ROP showed no statistically significant overall benefit of ET (18.1% vs 22.8% unfavorable outcomes; P=.08).Whenthe 6-year grating acuity results were analyzed according to a clinical algorithm (high-risk types 1 and 2 prethreshold ROP), a benefit was seen in type 1 eyes (16.4% vs 25.2%; P=.004) undergoing ET, but not in type 2 eyes (21.3% vs 15.9%; P=.29). Conclusion: Early treatment of eyes with type 1 ROP improves grating acuity outcomes, but ET for eyes with type 2 ROP does not. Application to Clinical Medicine: Type 1 eyes should be treated early; however, based on acuity results at 6 years of age, type 2 eyes should be cautiously monitored for progression to type 1 ROP. Trial Registration: Identifier: NCT00027222

Original languageEnglish (US)
Pages (from-to)840-846
Number of pages7
JournalArchives of Ophthalmology
Issue number7
StatePublished - Jul 2011


Dive into the research topics of 'Grating visual acuity results in the early treatment for retinopathy of prematurity study'. Together they form a unique fingerprint.

Cite this